Journal article
A Controlled Clinical Trial with a Specifically Configured RNA Drug, Poly(I). POly(C12U), in Chronic Fatigue Syndrome
Clinical infectious diseases, v 18(Supplement-1), pp S88-S95
Jan 1994
PMID: 8148460
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Chronic fatigue syndrome (CFS) is a physically debilitating illness associated with immunologic abnormalities, viral reactivation, and impairment of cognition. In a randomized, multicenter, placebo-controlled, double-blind study of 92 patients meeting the CFS case definition of the Centers for Disease Control and Prevention, the response of several laboratory and clinical variables to an antiviral and immunomodulatory drug, poly(I) · poly(C12U), was determined. Measures of clinical response included Karnofsky performance score, a cognition scale derived from a self-administered instrument assessing symptomatology (SCL-90-R), an activities of daily living scale, and exercise treadmill performance. After 24 weeks, patients receiving poly(I) · poly(C12U) had higher scores for both global performance and perceived cognition than did patients receiving placebo. In particular, patients given poly(I) · poly(C12U) had increased Karnofsky performance scores (P < .03), exhibited a greater ability to do work during exercise treadmill testing (P = .01), displayed an enhanced capacity to perform the activities of daily living (P < .04), had a reduced cognitive deficit (P = .05), and required less use of other medications (P < .05).
Metrics
Details
- Title
- A Controlled Clinical Trial with a Specifically Configured RNA Drug, Poly(I). POly(C12U), in Chronic Fatigue Syndrome
- Creators
- David R. Strayer - Hahnemann University HospitalWilliam A. Carter - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonIsadore Brodsky - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonPaul Cheney - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonDaniel Peterson - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonPatricia Salvato - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonCarol Thompson - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonMark Loveless - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonDavid E. Shapiro - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonWilliam Elsasser - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonDavid H. Gillespie - School of Medicine, Hahnemann University, and HEM Pharmaceuticals Corporation, Philadelphia, Pennsylvania, North Carolina, and Incline Village, Nevada, Houston, Texas, Portland, OregonChristina Z Thompson - Physical Therapy (and Rehabilitation Sciences)
- Publication Details
- Clinical infectious diseases, v 18(Supplement-1), pp S88-S95
- Publisher
- The University of Chicago Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Physical Therapy (and Rehabilitation Sciences)
- Web of Science ID
- WOS:A1994MR86400023
- Scopus ID
- 2-s2.0-0028009931
- Other Identifier
- 991019184034604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases
- Microbiology